Tharimmune (THAR) Competitors

BioVie (NASDAQ:BIVI) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Do analysts prefer BIVI or THAR?

Tharimmune has a consensus price target of $17.00, suggesting a potential upside of 865.91%. Given Tharimmune's higher possible upside, analysts clearly believe Tharimmune is more favorable than BioVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00
Tharimmune	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Which has better earnings and valuation, BIVI or THAR?

BioVie is trading at a lower price-to-earnings ratio than Tharimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$32.12M	-$7.91	-1.02
Tharimmune	N/A	N/A	-$12.20M	-$7.88	-0.22

Does the media favor BIVI or THAR?

In the previous week, BioVie had 1 more articles in the media than Tharimmune. MarketBeat recorded 1 mentions for BioVie and 0 mentions for Tharimmune. BioVie's average media sentiment score of 0.86 beat Tharimmune's score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company	Overall Sentiment
BioVie	Positive
Tharimmune	Neutral

Is BIVI or THAR more profitable?

BioVie's return on equity of -100.88% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-100.88%	-78.49%
Tharimmune	N/A	-489.33%	-264.34%

Which has more risk & volatility, BIVI or THAR?

BioVie has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500.

Do insiders and institutionals have more ownership in BIVI or THAR?

4.6% of BioVie shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 2.4% of BioVie shares are held by insiders. Comparatively, 10.0% of Tharimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

BioVie beats Tharimmune on 7 of the 13 factors compared between the two stocks.